| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Potential liquid biopsy biomarker for detecting GC and differentiating GC from controls/gastritis; higher levels associate with more aggressive clinicopathological features (e.g., deeper infiltration, nerve/vascular invasion, advanced TNM). |
| Molecular mechanism: |
Not specified; study emphasizes diagnostic modeling and experimental confirmation of circularity/stability rather than a mechanistic pathway in GC. |
| Biological pathway or process: |
not specified |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Clinical Sample Validation; ROC Analysis; Cohort Study; Bioinformatics Analysis; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Transfection; Agarose Gel Electrophoresis |
| Clinical significance: |
Upregulated in serum of GC patients; discriminates GC from controls (AUC 0.853) and contributes to a diagnostic model (GC-DM). Elevated expression correlates with TNM stage and invasiveness-related parameters. |
| Description: |
hsa_circ_0005265 is significantly up-regulated in the serum of gastric cancer patients (also elevated in gastritis vs healthy controls) and provides diagnostic value (AUC 0.853). It is used with hsa_circ_0001185 to build and validate a multicenter diagnostic model (GC-DM), and higher expression is associated with more invasive clinicopathological features such as deeper infiltration, nerve/vascular invasion, and higher TNM stage. |
| Confidence score: |
0.7734 |